Table 1.
Demographic characteristics of study participants.
| IM (N = 41) |
ID1 (N = 41) |
ID2 (N = 43) |
|
|---|---|---|---|
| Male, n (%) | 25 (61%) | 25 (61%) | 21 (49%) |
| Asian, n (%) | 41 (100) | 41 (100) | 43 (100) |
| Country of residence Thailand, n (%) | 41 (100) | 41 (100) | 43 (100) |
| Age at vaccination, years | |||
| Mean (SD) | 46.6 (27.4–66.0) | 42.3 (31.1–53.5) | 43.9 (33.0–54.8) |
| Median (IQR) | 45 (37–52) | 45 (31–52) | 47 (37–52) |
| Underlying diseases | |||
| Diabetes | 2 | 0 | 0 |
| Hypertension | 9 | 2 | 2 |
| CKD | 0 | 0 | 0 |
| Cirrhosis | 0 | 0 | 0 |
| Solid malignancy | 0 | 0 | 0 |
| Hematologic malignancy | 0 | 0 | 0 |
| Autoimmune disease | 0 | 0 | 0 |
| Baseline anti-SARS-CoV-2 spike protein level | |||
| GMC (95 %CI), BAU/mL | 48.8 (34.7–68.5) | 55.8 (40.1–77.7) | 85.1 (46.6–155.1) |
| Missing, n (%) | 0 (0) | 0 (0) | 0 (0) |
IM: intramuscular standard dose. ID1: 20% intradermal fractional dose. ID2: 20% intradermal fractional dose.